List view / Grid view
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
Efficacy research supports the widespread use of autonomous UVC disinfection for microbial surface decontamination, say AstraZeneca microbiology experts.
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
The company will now put a total of $4.5 billion into the Virginia site, expanding its remit to include active pharmaceutical ingredients for cancer drugs.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
7 October 2025 | By Rapid Micro Biosystems
This webinar showcases a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The planned succession will also see him become Chair of the German pharma company’s Executive Board in May 2026.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
In a surprise announcement, she will be replaced at the UK pharma company by its Chief Commercial Officer Luke Miels.
